Oral lichen planus: therapy and phenotype

Lorè, B; Saraceno, Rosita; Poladas, Giulio; Fida, Monika; Khoury, Charbel C.; Arcuri, C; Magnato, Roberto

doi:10.23736/s0392-0488.16.05399-2

Cited by 6 publications

(11 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Pain reduction in EOLP patients after intralesional PRP or i-PRF treatment was significant after 2 months (Bennardo et al, 2021;Sethi Ahuja et al, 2020) and 3 months of follow-up (Sobhy et al, 2020). Also, these results were similar to Loré et al (2016) and Merigo et al (2018) where they had reported significant symptoms reduction after 8 weeks of topical PRP application in erosive OLP, despite different frequencies of application (weekly and daily application, respectively) they showed the efficacy of PRP treatment for erosive OLP.…”

Section: T a B L E 1 Age Distribution Among Groupssupporting

confidence: 68%

“…Previous work done by Loré et al (2016) on topical application of PRP for EOLP lesions in four patients showed complete response in 50% of the lesions after 8 weeks of weekly interval treatment. His In the present study, no significant statistical results were recorded between groups regarding remission score after 3 months of treatment, while El-Komy et al (2015) reported longer remission when using intralesional PRP for treating oral erosions in PV patients.…”

Section: T a B L E 1 Age Distribution Among Groupsmentioning

confidence: 74%

See 1 more Smart Citation

Efficacy of intralesional injections of platelet‐rich plasma in patients with oral lichen planus: A pilot randomized clinical trial

Hijazi

Ahmed

Gaafar

2022

Clinical & Exp Dental Res

View full text Add to dashboard Cite

Objective: To evaluate the clinical efficacy of intralesional platelet-rich plasma (PRP) injections compared to intralesional triamcinolone acetonide (TA) injections in the treatment of erosive oral lichen planus (EOLP).Material and Methods: Twenty patients with EOLP were assigned randomly to either PRP or TA group. Patients received weekly intralesional injections for 4 weeks, and then followed up for 3 months on regular visits every 2 weeks. Pain scores using numerical pain score and clinical score were recorded by a blinded assessor each visit for all patients and remission score at the end of the trial was recorded.Results: Both groups showed significant improvement in the clinical parameters (pain and clinical score) "p = .001." Regarding remission of the lesions, 80% of patients in the PRP group showed complete remission compared to 70% in the TA group. However, there is no statistical significance when comparing the two groups in pain score, clinical score, or remission.Conclusions: PRP injections could be considered as an effective alternative single treatment modality for EOLP. The protocol for this study registered in Clinicaltrials.gov registry under the identifier number: NCT03293368.

show abstract

Section: T a B L E 1 Age Distribution Among Groupssupporting

confidence: 68%

Section: T a B L E 1 Age Distribution Among Groupsmentioning

confidence: 74%

Efficacy of intralesional injections of platelet‐rich plasma in patients with oral lichen planus: A pilot randomized clinical trial

Hijazi

Ahmed

Gaafar

2022

Clinical & Exp Dental Res

View full text Add to dashboard Cite

show abstract

“…In another study by Lore et al, 30 14 out of 20 individuals, showed improvement of OLP lesions after the treatment with Cyc‐A mouthwash. Notably, 6 participants did not show any responses to the treatment and no severe adverse effects were reported.…”

Section: Resultsmentioning

confidence: 89%

“…al topical Cyc‐A lipogel led to a uniform reduction in psoriasis plaques 35 . It is noteworthy that in psoriasis disease, nail involvement is a common feature 30 . In this vein, Cannavo et al reported that topical Cyc‐A is an acceptable treatment modality for nail psoriasis 30 ; however, another study showed no significant improvement in a case of nail psoriasis treated with topical Cyc‐A .…”

Section: Discussionmentioning

confidence: 99%

“…It is noteworthy that in psoriasis disease, nail involvement is a common feature 30 . In this vein, Cannavo et al reported that topical Cyc‐A is an acceptable treatment modality for nail psoriasis 30 ; however, another study showed no significant improvement in a case of nail psoriasis treated with topical Cyc‐A . 34 Regarding the treatment of pyoderma gangrenosum, Azizan et al reported satisfactory results following the use of topical Cyc‐A 35 .…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

A systematic review of the efficacy and safety of topical cyclosporine in dermatology

Sadeghi

Kalantari

Seirafianpour

et al. 2022

Dermatologic Therapy

View full text Add to dashboard Cite

Cyclosporine-A (Cyc-A) was initially prescribed as systemic therapy for patients receiving solid organ transplants or in patients with graft versus host disease (GVHD). Topical Cyc-A is an ideal form of cyclosporine in the treatment of mucocutaneous disorders as it causes fewer systemic side effects and has more stable results than steroids; however, poor absorption through the skin makes the development of new formulations necessary to improve skin permeability. The aim of this study was to evaluate the efficacy and safety of topical Cyc-A in different dermatological conditions. A thorough systematic review was performed on PubMed/Medline, Embase, Scopus, and Web of Science databases as well as Google Scholar, and relevant studies from 2000 until January 3, 2022, were selected. The study was conducted according to the Preferred Reporting Items for Systematic reviews and Meta-Analysis (PRISMA). Topical Cyc-A was observed to be an effective medication in the treatment of oral lichen planus, psoriasis, burning mouth syndrome, Pyoderma Gangrenosum, and Zoon's balanitis. Adverse side effects such as dysphagia, burning sensation, lips swelling, and gastrointestinal upset were reported following Cyc-A mouthwash use, whereas mild erythema, dryness, and fissuring of the skin were observed following the Cyc-A lipogel application. Topical Cyc-A was found to be a good alternative to traditional treatment regimens for immune-mediated mucocutaneous conditions. Cyc-A can be considered as a safe and efficient option in cases of long-term treatment as it does not have the same adverse effects of long-term steroids.

show abstract